Amicus Therapeutics, Inc. (NASDAQ:FOLD – Get Rating) Chairman John F. Crowley sold 10,468 shares of the business’s stock in a transaction that occurred on Thursday, September 15th. The stock was sold at an average price of $10.66, for a total transaction of $111,588.88. Following the completion of the transaction, the chairman now owns 856,897 shares of the company’s stock, valued at $9,134,522.02. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.
Amicus Therapeutics Price Performance
Shares of FOLD opened at $10.58 on Tuesday. The firm has a market cap of $2.97 billion, a PE ratio of -10.69 and a beta of 0.91. The company has a current ratio of 3.02, a quick ratio of 2.90 and a debt-to-equity ratio of 2.25. The firm has a fifty day simple moving average of $11.29 and a two-hundred day simple moving average of $9.61. Amicus Therapeutics, Inc. has a 1-year low of $5.91 and a 1-year high of $12.96.
Amicus Therapeutics (NASDAQ:FOLD – Get Rating) last announced its earnings results on Thursday, August 4th. The biopharmaceutical company reported ($0.21) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.02. Amicus Therapeutics had a negative net margin of 87.50% and a negative return on equity of 102.55%. During the same quarter last year, the firm posted ($0.19) earnings per share. On average, equities analysts anticipate that Amicus Therapeutics, Inc. will post -0.9 EPS for the current year.
Institutional Investors Weigh In On Amicus Therapeutics
Wall Street Analyst Weigh In
Separately, Morgan Stanley started coverage on shares of Amicus Therapeutics in a report on Friday, September 9th. They issued an “equal weight” rating and a $14.00 price objective for the company. Three equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company. According to data from MarketBeat, Amicus Therapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $15.00.
About Amicus Therapeutics
Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant based on in vitro assay data.
- Get a free copy of the StockNews.com research report on Amicus Therapeutics (FOLD)
- Oracle’s Short-Term Pain Could Be Your Long-Term Gain
- Lucid is Looking Like a Clear EV Winner
- Still Lovin’ It: Investors Keep Visiting McDonald’s
- Did FedEx Just Deliver A Buying Opportunity?
- Autozone Shifts Back Into Rally-Mode, New Highs Are In Sight
Receive News & Ratings for Amicus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.